Ekso Bionics Holdings Inc
$ 10.02
3.94%
26 Feb - close price
- Market Cap 34,348,800 USD
- Current Price $ 10.02
- High / Low $ 10.41 / 9.75
- Stock P/E N/A
- Book Value 2.54
- EPS -5.16
- Next Earning Report 2026-03-02
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.34 %
- ROE -1.08 %
- 52 Week High 13.27
- 52 Week Low 2.73
About
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the United States and internationally. The company is headquartered in Richmond, California.
Analyst Target Price
$9.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-24 | 2025-10-28 | 2025-07-28 | 2025-04-28 | 2025-03-03 | 2024-10-28 | 2024-07-29 | 2024-04-29 | 2024-03-04 | 2023-10-26 | 2023-07-27 | 2023-04-27 |
| Reported EPS | -1.56 | -0.54 | -1.24 | -0.12 | -0.14 | -0.1 | -0.13 | -0.2 | -0.22 | -0.24 | -0.31 | -0.33 |
| Estimated EPS | -0.35 | -0.085 | -0.08 | -0.16 | -0.08 | -0.1 | -0.13 | -0.16 | -0.11 | -0.31 | -0.28 | -0.31 |
| Surprise | -1.21 | -0.455 | -1.16 | 0.04 | -0.06 | 0 | 0 | -0.04 | -0.11 | 0.07 | -0.03 | -0.02 |
| Surprise Percentage | -345.7143% | -535.2941% | -1450% | 25% | -75% | 0% | 0% | -25% | -100% | 22.5806% | -10.7143% | -6.4516% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-02 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.08 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: EKSO
2026-02-23 21:15:28
Ekso Bionics Holdings, Inc. has released its annual 10-K report, detailing a 29% decrease in revenue to $12.8 million and an increased net loss of $(11.7) million for the year. The company is exploring strategic transactions, including a business combination with Applied Digital Corporation's cloud computing business, which could significantly alter its structure. Ekso Bionics faces ongoing financial risks, operational challenges, and supply chain disruptions, with its ability to continue as a going concern dependent on securing additional financing.
2026-02-18 22:57:43
Ekso Bionics (EKSO) is set to acquire Applied Digital Cloud Corporation, rebranding itself as ChronoScale Corporation. This strategic move, valued at 138,216,820 new Ekso shares, will result in Applied Digital holding approximately 97% of the combined entity, significantly diluting existing Ekso shareholders. The deal, subject to several conditions including stockholder approval and SEC clearance, aims to reposition Ekso Bionics in the technology sector through a cloud-focused subsidiary, despite current financial weaknesses and a Hold rating from analysts.
2026-02-17 11:27:51
Ekso Bionics will acquire Applied Digital Cloud, rename itself ChronoScale Corporation, and issue 138.2 million new shares, resulting in Applied Digital's affiliate owning approximately 97% of the combined entity. This business combination is contingent upon shareholder and regulatory approvals, a PIPE financing, and new governance terms that will give Applied Digital significant control. Analyst Spark views EKSO as Neutral due to weak financial performance despite strong revenue growth, with potential upside from corporate events balanced by execution and dilution uncertainties.
2026-02-17 11:27:51
Ekso Bionics announced a stock-for-stock business combination with Applied Digital Cloud, involving the issuance of 138.2 million new shares and a planned rebranding to ChronoScale. The deal will result in the contributor owning approximately 97% of the combined company, subject to stockholder approval and other conditions. Additionally, an Investor Rights Agreement will grant APLD investors scaled board designation and other rights, aligning governance with the new ownership structure.
2026-02-03 03:28:56
This page provides a comprehensive resource for investors and traders to access Ekso Bionics (EKSO) SEC filings, including annual 10-K reports, quarterly 10-Q statements, 8-K material event reports, and insider trading forms. It details the company's financial results, material events like stock offerings and executive compensation, and offers AI-powered summaries of key filings to clarify financial and corporate actions. Recent filings highlight executive equity awards, direct stock offerings, and the company's third-quarter financial performance.
2026-02-02 13:58:15
Zacks Investment Research highlights several stocks that have significantly outperformed market benchmarks due to their proprietary ranking systems. Five Below (FIVE), Novo Nordisk (NVO), and Ekso Bionics (EKSO) are among the featured companies, showcasing strong gains after receiving "Strong Buy" or "Buy" recommendations. The article details the performance of various Zacks portfolios, including those based on Zacks Rank, Recommendation Upgrades, Focus List, Earnings Certain Admiral Portfolio (ECAP), Earnings Certain Dividend Portfolio (ECDP), and Top 10 Stocks.
